{"id":"bmab-1000","safety":{"commonSideEffects":[]},"_chembl":null,"_fixedAt":"2026-03-30T13:17:03.699812","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a monoclonal antibody in phase 3 development by Biocon Biologics, Bmab 1000 is designed to modulate immune or disease-related pathways. Without confirmed public disclosure of its molecular target, the precise mechanism remains proprietary information held by the developer.","oneSentence":"Bmab 1000 is a monoclonal antibody targeting a specific molecular pathway, though the exact target is not publicly disclosed in available sources.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:04:39.349Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"_fixedFields":["pubmed(3)"],"trialDetails":[{"nctId":"NCT05345691","phase":"PHASE3","title":"Comparison of Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia® in Postmenopausal Women With Osteoporosis","status":"COMPLETED","sponsor":"Biocon Biologics UK Ltd","startDate":"2022-05-24","conditions":"Postmenopausal Women With Osteoporosis","enrollment":479},{"nctId":"NCT05323708","phase":"PHASE1","title":"Comparison of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Bmab 1000 and Prolia® in Normal Healthy Volunteers: DENARIUS: DENosumab Pharmacokinetic equivAlence tRIal in Healthy volUnteerS","status":"COMPLETED","sponsor":"Biocon Biologics UK Ltd","startDate":"2022-03-09","conditions":"Healthy Volunteers","enrollment":190}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"recentPublications":[{"date":"2022 Aug","pmid":"35687151","title":"On the spot immunocapture in targeted biomarker analysis using paper-bound streptavidin as anchor for biotinylated antibodies.","journal":"Analytical and bioanalytical chemistry"},{"date":"2009 Jun 19","pmid":"19830030","title":"Acute confusional state caused by Hashimoto's encephalopathy in a patient with hypothyroidism: a case report.","journal":"Cases journal"},{"date":"2008","pmid":"18457473","title":"Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator.","journal":"Drugs in R&D"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Bmab 1000","genericName":"Bmab 1000","companyName":"Biocon Biologics UK Ltd","companyId":"biocon-biologics-uk-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}